All Pathways
EndocrinologyEmergency

Diabetic Ketoacidosis (DKA) Management (ADA 2024)

Diabetic Ketoacidosis (DKA) Management (ADA 2024): Suspected DKA → Diagnostic Criteria → Initial Labs → Identify Precipitant → Fluid Resuscitation (STAR...

Interactive Decision Tree

Mini Map

Algorithm Steps

  1. Start

    Suspected DKA

    Hyperglycemia + ketosis + acidosis

    1. Action

      Diagnostic Criteria

      Confirm DKA diagnosis

      • TRIAD:
      • 1. Hyperglycemia: Glucose >250 mg/dL
      • (Can be euglycemic with SGLT2i)
      • 2. Ketosis: Serum/urine ketones +
      • (Beta-hydroxybutyrate >3 mmol/L)
      • 3. Acidosis: pH <7.3, HCO3 <18 mEq/L
      • SEVERITY:
      • - Mild: pH 7.25-7.3, HCO3 15-18
      • - Moderate: pH 7.0-7.24, HCO3 10-15
      • - Severe: pH <7.0, HCO3 <10
      1. Action

        Initial Labs

        Comprehensive metabolic assessment

        • STAT labs:
        • - BMP (glucose, K+, HCO3, BUN, Cr)
        • - VBG or ABG (pH, pCO2)
        • - Beta-hydroxybutyrate
        • - Serum osmolality
        • - CBC
        • - UA with ketones
        • CALCULATE:
        • - Anion gap = Na - (Cl + HCO3)
        • - Normal: 8-12
        • - DKA: Usually >20
        • - Corrected Na+ = Measured + 1.6×[(glucose-100)/100]
        1. Action

          Identify Precipitant

          The '5 I's'

          • INFECTION (most common)
          • - UTI, pneumonia, skin
          • - COVID-19, influenza
          • INSULIN (missed doses/pump failure)
          • INFARCTION (MI, stroke, mesenteric)
          • INTOXICATION (cocaine, alcohol)
          • INITIAL PRESENTATION (new T1DM)
          • Other: Pregnancy, steroids, pancreatitis
          1. Warning

            Fluid Resuscitation (START FIRST)

            IV fluids are priority #1

            • INITIAL BOLUS:
            • - 0.9% NS: 15-20 mL/kg/hr (1-1.5L) first hour
            • SUBSEQUENT:
            • - If corrected Na+ low: 0.9% NS at 250-500 mL/hr
            • - If corrected Na+ normal/high: 0.45% NS at 250-500 mL/hr
            • WHEN GLUCOSE <200 mg/dL:
            • - Switch to D5-0.45% NS
            • - Maintain glucose 150-200 mg/dL
            • GOAL: 3-6L in first 24h typically
            1. Action

              Potassium Replacement

              Critical - check before insulin

              • BEFORE INSULIN:
              • - K+ <3.3: HOLD insulin, give 20-30 mEq/hr
              • - K+ 3.3-5.2: Add 20-30 mEq to each liter fluid
              • - K+ >5.2: Do not give K+, recheck q2h
              • GOAL: K+ 4-5 mEq/L
              • MONITORING:
              • - Q2h initially with insulin
              • - ECG if K+ <3 or >6
              • NOTE: Total body K+ depleted even if serum normal
              1. Action

                Bicarbonate (Rarely Needed)

                Only for severe acidosis

                • INDICATIONS (controversial):
                • - pH <6.9 (some say <7.0)
                • - Severe hyperkalemia with ECG changes
                • - Hemodynamic instability
                • IF GIVEN:
                • - 100 mEq NaHCO3 in 400 mL water + 20 mEq KCl
                • - Infuse over 2 hours
                • - Repeat if pH remains <7.0
                • AVOID routine use (may worsen outcomes)
                1. Action

                  Monitoring

                  Frequent reassessment

                  • GLUCOSE: Q1h
                  • ELECTROLYTES: Q2-4h initially
                  • ANION GAP: Q4h (calculate from BMP)
                  • VBG/ABG: Q2-4h until stable
                  • CLINICAL: Mental status, I/O
                  • RESOLUTION CRITERIA:
                  • - Anion gap <12
                  • - pH >7.3
                  • - HCO3 ≥15
                  • - Patient eating
                  1. Action

                    Transition to SubQ Insulin

                    When DKA resolved

                    • CRITERIA TO TRANSITION:
                    • - Anion gap normalized
                    • - pH >7.3
                    • - Tolerating PO
                    • OVERLAP:
                    • - Give SubQ basal insulin
                    • - Continue IV insulin 1-2 hours after SubQ
                    • - Then discontinue drip
                    • NEW DIABETIC:
                    • - Start 0.5-0.8 U/kg/day total
                    • - 50% basal, 50% prandial
                    1. Outcome

                      Outcomes

                      Follow-up

                      • Mortality: <1% with proper treatment
                      • Cerebral edema: <1% adults (higher in peds)
                      • Education before discharge
                      • Sick day rules
                      • Endocrine follow-up
                      • Address precipitant
            2. Action

              Insulin Therapy

              Start after K+ confirmed >3.3

              • REGULAR INSULIN IV DRIP:
              • - 0.1 U/kg/hr (no bolus per ADA 2024)
              • - OR: 0.14 U/kg/hr if no initial bolus
              • TARGET:
              • - Glucose drop: 50-70 mg/dL/hr
              • - If not dropping: Double rate
              • WHEN GLUCOSE <200 mg/dL:
              • - Reduce to 0.02-0.05 U/kg/hr
              • - Add D5 to fluids
              • - Maintain glucose 150-200
              • DO NOT STOP INSULIN until anion gap closes

Guideline Source

ADA Standards of Care in Diabetes 2024 + JBDS DKA Guidelines

Clinical Safety Information

Clinical Decision Support — Not a Substitute for Clinical Judgment

Individual patient factors may require deviation from these recommendations.

Known Limitations

  • Pediatric dosing differs
  • Cerebral edema risk (especially pediatric)
  • Euglycemic DKA with SGLT2 inhibitors
  • Must identify precipitant

Applicable Regions

USEU
Version 1Next review: 2027-01-11

Frequently Asked Questions

What is the Diabetic Ketoacidosis (DKA) Management (ADA 2024)?

The Diabetic Ketoacidosis (DKA) Management (ADA 2024) is a emergency clinical algorithm for Endocrinology. It provides a structured decision tree to guide clinical decision-making, based on ADA Standards of Care in Diabetes 2024 + JBDS DKA Guidelines.

What guideline is the Diabetic Ketoacidosis (DKA) Management (ADA 2024) based on?

This algorithm is based on ADA Standards of Care in Diabetes 2024 + JBDS DKA Guidelines (DOI: 10.2337/dc24-SINT).

What are the limitations of the Diabetic Ketoacidosis (DKA) Management (ADA 2024)?

Known limitations include: Pediatric dosing differs; Cerebral edema risk (especially pediatric); Euglycemic DKA with SGLT2 inhibitors; Must identify precipitant. Individual patient factors may require deviation from these recommendations.

Get AI-Powered Analysis Alongside This Algorithm

In AttendMe.ai, the Diabetic Ketoacidosis (DKA) Management (ADA 2024) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.

Try AttendMe Free